Literature DB >> 7731718

The motogenic and mitogenic responses to HGF are amplified by the Shc adaptor protein.

G Pelicci1, S Giordano, Z Zhen, A E Salcini, L Lanfrancone, A Bardelli, G Panayotou, M D Waterfield, C Ponzetto, P G Pelicci.   

Abstract

The receptor of Hepatocyte Growth Factor-Scatter Factor (HGF) is a tyrosine kinase which regulates cell motility and growth. After ligand-induced tyrosine phosphorylation, the HGF receptor associates with the Shc adaptor, via the SH2 domain. Site-directed mutagenesis of the HGF receptor indicates that phosphotyrosines Y1349VHV and Y1356VNV can work as docking sites for Shc. The Kd of this interaction, measured in real time using synthetic phosphopeptides and recombinant Shc on a BIAcore biosensor, is 150 nm for both sites. After stimulation of the HGF receptor, Shc is phosphorylated on Y317VNV, generating an high affinity binding site for Grb2 (Kd = 15 nM). This duplicates the high affinity binding site for Grb2 present on the HGF receptor (Y1356VNV). Thus HGF stimulation can trigger the Ras pathway by recruiting Grb2 both directly through the receptor, and indirectly, through Shc. Overexpression of wild-type Shc, but not of the Y317-->F mutant, enhances cell migration and growth in response to HGF. These data show that Shc is a relevant substrate of the HGF receptor, and works as an 'amplifier' of the motogenic as well as of the mitogenic response.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7731718

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  54 in total

Review 1.  HGF/SF in mammary epithelial growth and morphogenesis: in vitro and in vivo models.

Authors:  T Kamalati; B Niranjan; J Yant; L Buluwela
Journal:  J Mammary Gland Biol Neoplasia       Date:  1999-01       Impact factor: 2.673

2.  The multisubstrate docking site of the MET receptor is dispensable for MET-mediated RAS signaling and cell scattering.

Authors:  D Tulasne; R Paumelle; K M Weidner; B Vandenbunder; V Fafeur
Journal:  Mol Biol Cell       Date:  1999-03       Impact factor: 4.138

3.  Sequential activation of ERK and repression of JNK by scatter factor/hepatocyte growth factor in madin-darby canine kidney epithelial cells.

Authors:  R Paumelle; D Tulasne; C Leroy; J Coll; B Vandenbunder; V Fafeur
Journal:  Mol Biol Cell       Date:  2000-11       Impact factor: 4.138

4.  An overview of the c-MET signaling pathway.

Authors:  Shawna Leslie Organ; Ming-Sound Tsao
Journal:  Ther Adv Med Oncol       Date:  2011-11       Impact factor: 8.168

5.  Src and Ras are involved in separate pathways in epithelial cell scattering.

Authors:  B Boyer; S Roche; M Denoyelle; J P Thiery
Journal:  EMBO J       Date:  1997-10-01       Impact factor: 11.598

Review 6.  Current advances of targeting HGF/c-Met pathway in gastric cancer.

Authors:  Aristomenis Anestis; Ilianna Zoi; Michalis V Karamouzis
Journal:  Ann Transl Med       Date:  2018-06

7.  Sch proteins are localized on endoplasmic reticulum membranes and are redistributed after tyrosine kinase receptor activation.

Authors:  L V Lotti; L Lanfrancone; E Migliaccio; C Zompetta; G Pelicci; A E Salcini; B Falini; P G Pelicci; M R Torrisi
Journal:  Mol Cell Biol       Date:  1996-05       Impact factor: 4.272

8.  Focal adhesion kinase and Src phosphorylations in HGF-induced proliferation and invasion of human cholangiocarcinoma cell line, HuCCA-1.

Authors:  Urai Pongchairerk; Jun-Lin Guan; Vijittra Leardkamolkarn
Journal:  World J Gastroenterol       Date:  2005-10-07       Impact factor: 5.742

Review 9.  Hepatocyte growth factor/scatter factor-Met signaling in tumorigenicity and invasion/metastasis.

Authors:  M Jeffers; S Rong; G F Vande Woude
Journal:  J Mol Med (Berl)       Date:  1996-09       Impact factor: 4.599

10.  Polyomavirus large T antigen induces alterations in cytoplasmic signalling pathways involving Shc activation.

Authors:  V Gottifredi; G Pelicci; E Munarriz; R Maione; P G Pelicci; P Amati
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.